Viatris (VTRS) Return on Capital Employed (2020 - 2026)
Viatris' (VTRS) quarterly Return on Capital Employed came in at 0.46% in Q1 2026, up 944.0% year-on-year from 0.04% in Q1 2025, and up 105.28% quarter-over-quarter from 8.74% in Q4 2025.
Viatris (VTRS) Return on Capital Employed (2020 - 2026) Analysis & Trends
Viatris' Return on Capital Employed history runs 7 years deep, the most recent figure standing at 0.46% for Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 944.0% year-over-year to 0.46% in Q1 2026; TTM through Mar 2026 was 0.46%, a 944.0% increase from a year earlier, with the FY2025 full-year figure at 8.26%, down 828.0% from the prior year.
- Return on Capital Employed grew to 0.46% in Q1 2026 per VTRS's latest filing, from 8.74% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 4.01% in Q3 2022 and bottomed at 8.98% in Q1 2025.
- The 5-year median for Return on Capital Employed is 1.43% (2024), against an average of 0.6%.
- Across the five-year window, Return on Capital Employed slumped 1041 bps in 2025 and surged 944 bps in 2026, its largest moves.
- Year by year, Return on Capital Employed stood at 3.79% in 2022, then plunged by 50 bps to 1.89% in 2023, then sank by 99 bps to 0.03% in 2024, then sank by 32427 bps to 8.74% in 2025, then soared by 105 bps to 0.46% in 2026.
- Per Business Quant, the three latest VTRS Return on Capital Employed figures stand at 0.46% (Q1 2026), 8.74% (Q4 2025), and 8.6% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 21.43% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.24% |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 0.91% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.46% |
| Dec 31, 2025 | -8.74% |
| Sep 30, 2025 | -8.60% |
| Jun 30, 2025 | -8.31% |
| Mar 31, 2025 | -8.98% |
| Dec 31, 2024 | 0.03% |
| Sep 30, 2024 | -0.71% |
| Jun 30, 2024 | -0.10% |
| Mar 31, 2024 | 1.43% |
| Dec 31, 2023 | 1.89% |
| Sep 30, 2023 | 2.43% |
| Jun 30, 2023 | 2.66% |
| Mar 31, 2023 | 3.00% |
| Dec 31, 2022 | 3.79% |
| Sep 30, 2022 | 4.01% |
| Jun 30, 2022 | 3.44% |
| Mar 31, 2022 | 2.11% |
| Dec 31, 2021 | -0.07% |
| Sep 30, 2021 | -1.78% |
| Jun 30, 2021 | -3.14% |